Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction

Annals of Surgical Oncology

Volumn 14, Issue 7, 2007, Pages 2010-2017

  Fujitani, Kazumasa ^a   Ajani, Jaffer A ^a   Crane, Christopher H ^a   Feig, Barry W ^a   Pisters, Peter W ^a   Janjan, Nora ^a   Walsh, Garrett L ^a   Swisher, Stephen G ^a   Vaporciyan, Ara A ^a   Rice, David ^a   Welch, Angela ^a   Baker, Jackie ^a   Faust, Josephine ^a   Mansfield, Paul F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gastric cancer; Gastroesophageal cancer; Induction chemotherapy; Morbidity; Mortality; Preoperative chemoradiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; BODY MASS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; STOMACH; STOMACH ADENOCARCINOMA; SURGICAL MORTALITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DATABASES; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; STOMACH NEOPLASMS;

EID: 34250793357     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9198-2     Document Type: Review

References (25)

1. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80:2333-2341
2. Ekstrom AM, Hansson LE, Signorello LB, Lindgren A, Bergstrom R, Nyren O. Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma - a population-based study in Sweden. Br J Cancer 2000; 83:391-396
3. Wanebo HJ, Kennedy BJ, Chmiel J, Steele Jr G, Winchester D, Osteen R. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993; 218:583-592
4. Allum W, Cunningham D, Weeden S, for the UK NCRI Upper GI Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2003; 21(Suppl):abstr 998
5. Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22:2774-2780
6. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237-1244
7. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia-report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42:929-934
8. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PWT, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8:519-524
9. Skoropad VY, Berdov BA, Zagrebin VM. Preoperative radiotherapy in combination with metronidazole for resectable gastric cancer: long-term results of a phase 2 study. Eur J Surg Oncol 2003; 29:166-170
10. Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345:745-748
11. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P, for the Surgical Cooperative Group. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347:995-999
12. Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22:2767-2773
13. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005; 92:1099-1102
14. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991; 126:1469-1473
15. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L, The Italian Gastrointestinal Tumor Study Group. Total versus subtotal gastrectomy: surgical morbidity and mortality in a multicenter Italian randomized trial. Ann Surg 1997; 226:613-620
16. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449-461
17. Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30:303-308
18. Birkmeyer JD, Siewers AE, Finlayson EVA et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128-1137
19. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117-2127
20. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131:6-15
21. Sasako M, for the Dutch Gastric Cancer Study Group. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997; 84:1567-1571
22. Hartgrink HH, van de Velde CJH, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004; 22:2069-2077
23. Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A, on behalf of the Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005; 92:1103-1109
24. Cuschieri A, Weeden S, Fielding J et al., for the Surgical Co-operative Group. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79:1522-1530
25. Cunningham D, Allum WH, Stenning SP, Weeden S, for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2005; 23(Suppl): abstr 4001